2026-06-14T03:32:35Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/94482025-04-24T18:27:20Zcom_20.500.12105_2052com_20.500.12105_2051com_20.500.12105_15322col_20.500.12105_19609col_20.500.12105_16938col_20.500.12105_16988

00925njm 22002777a 4500 dc Solana, Jose Carlos author Ramírez, Laura author Cook, Emma CL author Hernández-García, Elena author Sacristán, Silvia author Martín, M Elena author González, Víctor Manuel author Reguera, Rosa María author Balaña-Fouce, Rafael author Fresno, Manuel author Requena, José María author Iborra, Salvador author Soto, Manuel author 2020-03-23 Leishmania infantum parasites cause a severe form of visceral leishmaniasis in human and viscerocutaneous leishmaniasis in dogs. Recently, we reported that immunization with an attenuated L. infantum cell line, lacking the hsp70-II gene, protects against the development of murine cutaneous leishmaniasis. In this work, we analyzed the vaccine potential of this cell line towards the long-term protection against murine visceral leishmaniasis. This model shows an organ-dependent evolution of the disease. The infection can resolve in the liver but chronically affect spleen and bone marrow. Twelve weeks after subcutaneous administration of attenuated L. infantum, Bagg Albino (BALB/c) mice were challenged with infective L. infantum parasites expressing the luciferase-encoding gene. Combining in vivo bioimaging techniques with limiting dilution experiments, we report that, in the initial phase of the disease, vaccinated animals presented lower parasite loads than unvaccinated animals. A reduction of the severity of liver damage was also detected. Protection was associated with the induction of rapid parasite-specific IFN-γ production by CD4+ and CD8+ T cells. However, the vaccine was unable to control the chronic phase of the disease, since we did not find differences in the parasite burdens nor in the immune response at that time point. Vaccines (Basel). 2020 Mar 23;8(1). pii: E141. 10.3390/vaccines8010141 2076-393X Vaccines 32210040 http://hdl.handle.net/20.500.12105/9448 IFN-γ T-cells Attenuated parasites Mice Vaccine Visceral leishmaniasis Subcutaneous Immunization of Leishmania HSP70-II Null Mutant Line Reduces the Severity of the Experimental Visceral Leishmaniasis in BALB/c Mice